ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
29 Aug 2022
29 Aug 2022
Historique:
received:
20
12
2021
accepted:
09
08
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Tumor phenotype is shaped both by transforming genomic alterations and the normal cell-of-origin. We identified a cell-of-origin associated prognostic gene expression signature, ET-9, that correlates with remarkably shorter overall and relapse free breast cancer survival, 8.7 and 6.2 years respectively. The genes associated with the ET-9 signature are regulated by histone deacetylase 7 (HDAC7) partly through ZNF92, a previously unexplored transcription factor with a single PubMed citation since its cloning in 1990s. Remarkably, ZNF92 is distinctively over-expressed in breast cancer compared to other tumor types, on a par with the breast cancer specificity of the estrogen receptor. Importantly, ET-9 signature appears to be independent of proliferation, and correlates with outcome in lymph-node positive, HER2+, post-chemotherapy and triple-negative breast cancers. These features distinguish ET-9 from existing breast cancer prognostic signatures that are generally related to proliferation and correlate with outcome in lymph-node negative, ER-positive, HER2-negative breast cancers. Our results suggest that ET-9 could be also utilized as a predictive signature to select patients for HDAC inhibitor treatment.
Identifiants
pubmed: 36038558
doi: 10.1038/s41523-022-00474-2
pii: 10.1038/s41523-022-00474-2
pmc: PMC9424319
doi:
Types de publication
Journal Article
Langues
eng
Pagination
99Informations de copyright
© 2022. The Author(s).
Références
Adv Exp Med Biol. 2019;1210:67-86
pubmed: 31900905
PLoS One. 2009;4(2):e4544
pubmed: 19229342
Cancer Sci. 2021 Dec;112(12):4883-4893
pubmed: 34632664
Cancer Sci. 2007 Oct;98(10):1592-6
pubmed: 17651454
Mol Cytogenet. 2018 May 10;11:31
pubmed: 29760781
Breast Cancer Res Treat. 2013 Aug;140(3):495-504
pubmed: 23912959
Cell. 2012 Aug 3;150(3):549-62
pubmed: 22863008
Cancer Res. 2019 Jan 1;79(1):61-71
pubmed: 30401712
Cancer Cell. 2013 Aug 12;24(2):182-96
pubmed: 23948298
Breast Cancer Res. 2021 Feb 1;23(1):17
pubmed: 33526044
PLoS One. 2013;8(3):e58483
pubmed: 23505515
Int J Mol Sci. 2019 Jun 08;20(11):
pubmed: 31181796
NMR Biomed. 2016 Aug;29(8):1098-107
pubmed: 27356959
PLoS Comput Biol. 2014 Mar 06;10(3):e1003450
pubmed: 24604070
Cell. 2008 Jun 13;133(6):994-1005
pubmed: 18555776
Oncotarget. 2017 Sep 28;8(60):101634-101648
pubmed: 29254192
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):345-50
pubmed: 11162943
Front Med (Lausanne). 2018 Sep 04;5:248
pubmed: 30234119
Genet Test Mol Biomarkers. 2021 Mar;25(3):227-235
pubmed: 33734898
Oncogene. 2019 Sep;38(39):6599-6614
pubmed: 31375747
Am J Clin Pathol. 2018 Apr 25;149(6):474-483
pubmed: 29659669
JNCI Cancer Spectr. 2017 Dec 11;1(1):pkx008
pubmed: 31360834
J Theor Biol. 2019 Jun 21;471:42-50
pubmed: 30930063
World J Surg Oncol. 2020 Apr 13;18(1):73
pubmed: 32284070
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
pubmed: 12829800
Onco Targets Ther. 2018 Oct 11;11:6827-6838
pubmed: 30349315
Cancer Prev Res (Phila). 2016 Oct;9(10):773-776
pubmed: 27435221
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
J Pathol. 2008 Dec;216(4):387-93
pubmed: 18853439
Oncol Lett. 2020 Jan;19(1):795-804
pubmed: 31897196
Patterns (N Y). 2021 Apr 09;2(4):100226
pubmed: 33982021
Lancet Oncol. 2021 Apr;22(4):476-488
pubmed: 33721561
EBioMedicine. 2020 Feb;52:102646
pubmed: 32062352
Mol Cell Biol. 2007 Jul;27(13):4784-95
pubmed: 17470557
Nature. 1999 Jul 29;400(6743):464-8
pubmed: 10440377
Cancer Discov. 2021 Mar;11(3):660-677
pubmed: 34009137
Cell Death Dis. 2020 May 6;11(5):322
pubmed: 32376822
Oncotarget. 2015 Apr 20;6(11):9018-30
pubmed: 25940703
Genome Med. 2021 Feb 10;13(1):23
pubmed: 33568205
Oncogene. 2017 Mar 23;36(12):1707-1720
pubmed: 27694895
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807717
Yale J Biol Med. 2002 Sep-Dec;75(5-6):247-60
pubmed: 14580107
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18378-83
pubmed: 22042860
Oncotarget. 2017 Feb 21;8(8):14003-14016
pubmed: 28122328
BMC Genomics. 2013 May 17;14:336
pubmed: 23682826
Commun Biol. 2020 Jul 27;3(1):397
pubmed: 32719399
Mol Cancer Res. 2013 Jan;11(1):74-85
pubmed: 23131994
Nature. 2022 Apr;604(7905):354-361
pubmed: 35355015
BMC Bioinformatics. 2016 Jun 29;17:259
pubmed: 27358049
JAMA. 2008 Oct 1;300(13):1580-1
pubmed: 18827215
Cancer Cell. 2004 Jun;5(6):539-51
pubmed: 15193257
Hum Genet. 2008 Apr;123(3):247-55
pubmed: 18210156
EMBO J. 1993 Apr;12(4):1363-74
pubmed: 8467795
Genes Dev. 2020 Aug 1;34(15-16):1017-1032
pubmed: 32747478
PLoS One. 2013 May 28;8(5):e64600
pubmed: 23724067
Clin Epigenetics. 2018 Jul 31;10(1):100
pubmed: 30064501
Life (Basel). 2021 Dec 23;12(1):
pubmed: 35054414
Biomark Insights. 2010 Nov 28;5:129-38
pubmed: 21151591
J Clin Invest. 2014 Feb;124(2):859-70
pubmed: 24463450
Stem Cell Res. 2018 Jan;26:1-7
pubmed: 29179130
Front Oncol. 2021 Jan 21;10:615400
pubmed: 33552990
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-12
pubmed: 33793316
Int J Oncol. 2019 Mar;54(3):1112-1122
pubmed: 30628670
Hum Pathol. 2018 May;75:167-178
pubmed: 29409837
PLoS One. 2013 Nov 26;8(11):e80314
pubmed: 24303006
Int J Cancer. 2022 Feb 1;150(3):450-460
pubmed: 34569064
PLoS One. 2013 Sep 16;8(9):e74250
pubmed: 24066126
PLoS One. 2013 Dec 11;8(12):e82125
pubmed: 24349199
J Intern Med. 2011 Nov;270(5):428-46
pubmed: 21752111
Sci Rep. 2021 Jan 8;11(1):156
pubmed: 33420139
Int J Mol Sci. 2021 Dec 13;22(24):
pubmed: 34948181
Neoplasia. 2020 Dec;22(12):759-769
pubmed: 33142240
PLoS One. 2017 Aug 29;12(8):e0183458
pubmed: 28850621
J Oral Pathol Med. 2017 Apr;46(4):276-283
pubmed: 28178760
Cancer Inform. 2014 Dec 09;13(Suppl 4):53-64
pubmed: 25574126
PLoS Comput Biol. 2011 Oct;7(10):e1002240
pubmed: 22028643
Philos Trans A Math Phys Eng Sci. 2022 Jul 11;380(2227):20210246
pubmed: 35599558
Science. 2021 Aug 13;373(6556):737-738
pubmed: 34385380
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Ther Adv Med Oncol. 2021 Aug 14;13:17588359211038467
pubmed: 34408795
Breast J. 2008 May-Jun;14(3):261-7
pubmed: 18373644
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
J Natl Cancer Inst. 2016 Apr 29;108(9):
pubmed: 27130929
Am J Hematol. 2020 Jan;95(1):57-67
pubmed: 31659781
JHEP Rep. 2021 Jan 19;3(2):100226
pubmed: 33665585
Oncol Lett. 2018 Mar;15(3):3524-3531
pubmed: 29456726
Bioinformatics. 2007 Dec 1;23(23):3251-3
pubmed: 17644558
Cancer Cell. 2007 Aug;12(2):160-70
pubmed: 17692807
Medicine (Baltimore). 2019 Jul;98(30):e16534
pubmed: 31348270
N Engl J Med. 2009 Feb 19;360(8):790-800
pubmed: 19228622
Cancer Res. 2013 Jul 15;73(14):4461-73
pubmed: 23720051
Genes (Basel). 2021 Dec 31;13(1):
pubmed: 35052441
PLoS One. 2014 Aug 25;9(8):e105836
pubmed: 25153832
Expert Rev Anticancer Ther. 2014 Dec;14(12):1385-9
pubmed: 25263303
Cell. 2008 Jul 11;134(1):62-73
pubmed: 18614011
J Cancer. 2018 Sep 8;9(19):3603-3612
pubmed: 30310518
Breast Cancer Res Treat. 2015 Aug;153(1):57-66
pubmed: 26223813
Cancer Gene Ther. 2022 May;29(5):428-436
pubmed: 34744163
BMC Cell Biol. 2014 Jun 10;15:20
pubmed: 24915897
J Med Internet Res. 2021 Jul 26;23(7):e27633
pubmed: 34309564
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Cell Stem Cell. 2010 May 7;6(5):479-91
pubmed: 20452322